Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak.
Med Oncol
; 37(6): 51, 2020 Apr 24.
Article
in English
| MEDLINE | ID: covidwho-116317
ABSTRACT
As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Antineoplastic Agents, Alkylating
/
Pandemics
/
Betacoronavirus
/
Temozolomide
/
Lymphopenia
/
Neoplasms
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Med Oncol
Journal subject:
Neoplasms
Year:
2020
Document Type:
Article
Affiliation country:
S12032-020-01376-8
Similar
MEDLINE
...
LILACS
LIS